Novo Nordisk A/S (NYSE:NVO) Trading 0.4% Higher – What’s Next?

Shares of Novo Nordisk A/S (NYSE:NVO) were up 0.4% during trading on Thursday . The stock traded as high as $90.19 and last traded at $89.87. Approximately 2,446,901 shares changed hands during trading, a decline of 73% from the average daily volume of 9,114,777 shares. The stock had previously closed at $89.55.

Analysts Set New Price Targets

NVO has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Up 1.6 %

The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $406.91 billion, a P/E ratio of 27.56, a P/E/G ratio of 0.90 and a beta of 0.45. The firm’s 50-day moving average price is $84.82 and its 200 day moving average price is $106.90.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently made changes to their positions in NVO. Center for Financial Planning Inc. boosted its holdings in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its position in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after buying an additional 300 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Finally, Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. Institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.